S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Guardant Health (GH) Stock Forecast & Price Target

$19.42
-2.85 (-12.80%)
(As of 04:00 PM ET)

Guardant Health Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$43.83
125.71% Upside
High Forecast$55.00
Average Forecast$43.83
Low Forecast$27.00
TypeCurrent Forecast
2/23/23 to 2/23/24
1 Month Ago
1/24/23 to 1/24/24
3 Months Ago
11/25/22 to 11/25/23
1 Year Ago
2/23/22 to 2/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$43.83$48.62$49.20$82.53
Predicted Upside125.71% Upside86.52% Upside87.83% Upside82.61% Upside
Get Guardant Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.


GH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Guardant Health Stock vs. The Competition

TypeGuardant HealthMedical CompaniesS&P 500
Consensus Rating Score
2.87
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside119.48% Upside1,076.46% Upside7.77% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/23/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$60.00 ➝ $45.00+126.70%
2/23/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$50.00 ➝ $45.00+123.44%
1/29/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$43.00 ➝ $37.00+57.31%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
11/13/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$27.00+25.12%
11/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$55.00 ➝ $50.00+111.24%
10/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$50.00+72.35%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$34.00+23.10%
9/27/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$40.00+55.04%
9/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
5/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$60.00 ➝ $55.00+129.26%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+65.70%
2/24/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$60.00 ➝ $50.00+77.37%
2/24/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$70.00 ➝ $53.00+104.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:34 PM ET.












GH Price Target - Frequently Asked Questions

What is Guardant Health's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Guardant Health stock is Moderate Buy based on the current 2 hold ratings and 13 buy ratings for GH. The average twelve-month price prediction for Guardant Health is $43.83 with a high price target of $55.00 and a low price target of $27.00. Learn more on GH's analyst rating history.

Do Wall Street analysts like Guardant Health more than its competitors?

Analysts like Guardant Health more than other Medical companies. The consensus rating score for Guardant Health is 2.87 while the average consensus rating score for medical companies is 2.68. Learn more on how GH compares to other companies.

Does Guardant Health's stock price have much upside?

According to analysts, Guardant Health's stock has a predicted upside of 78.30% based on their 12-month stock forecasts.

What analysts cover Guardant Health?

Guardant Health has been rated by Canaccord Genuity Group, Guggenheim, JPMorgan Chase & Co., The Goldman Sachs Group, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GH) was last updated on 2/23/2024 by MarketBeat.com Staff